Skip to navigation Skip to content

Clinical Trial: Siponimod in MS

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To explore safety and tolerability
Number of Subjects: 15
Medication: siponimod
Location: California
Institutions: SC3 Research, Pasadena Contact Information
Roxanne Cabading, ext. 799
(626) 250 2070
roxanne.cabading@neurosearch-usa.com

Funding:

Novartis

Description

To assess early phase safety and tolerability of converting from approved oral and injectable disease-modifying therapies for relapsing MS to siponimod. The results of this study will guide clinically relevant decisions related to the transition from frequently used therapies to siponimod and provide clinically relevant data on safety and tolerability for healthcare providers who are considering converting people with MS from currently approved therapies to siponimod.

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.